Mirum Pharmaceuticals Return on Equity

Mirum Pharmaceuticals (MIRM) currently reports a ROE of 8253.76%. That is above the Healthcare sector average of 22.01%. Use the charts on this page to explore Mirum Pharmaceuticals's ROE history and peer comparisons.

Mirum Pharmaceuticals's ROE of 8253.76% is higher than the Healthcare sector average of 22.01%. That is roughly 37400.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Mirum Pharmaceuticals's current 8253.76% should be judged against Healthcare norms (sector average: 22.01%) and against MIRM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 8253.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.01%. From there, open related valuation or income-statement pages for Mirum Pharmaceuticals, and consider following MIRM for alerts when major investors trade the stock.

Mirum Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 8253.76% versus a sector average near 22.01%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MIRM with unrelated industries.